PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration:
The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday).